Payment overview · 2025
General Payments
$1,293.96
68 reported records · 18 companies
Healthcare provider profile · identity verified
Lydia Chaney Tanner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DOUGLAS, GA · NPI 1790799740
Verified facts
What the public records show
CMS Open Payments records show Lydia Chaney Tanner, M.D. received $1,293.96 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $283.72 | 21.9% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $222.44 | 17.2% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.03 | 16.1% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.89 | 8.7% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.27 | 6.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.83 | 5.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.97 | 4.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.63 | 3.7% | 3 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $46.56 | 3.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.11 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.00 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.76 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.73 | 1.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.43 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.33 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.06 | 1.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.02 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.18 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,293.96 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $202.11 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $176.21 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $150.83 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.88 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $111.89 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $109.14 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.56 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.15 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.27 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $71.83 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.63 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.63 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $46.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 192 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 201 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 784 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 735 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 704 | 155 |
| Losartan Potassium | Losartan Potassium | 543 | 134 |
| Gabapentin | Gabapentin | 482 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 453 | 119 |
| Escitalopram Oxalate | Escitalopram Oxalate | 404 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 376 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 374 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 84 |
| Meloxicam | Meloxicam | 321 | 79 |
| Metformin Hcl Er | Metformin Hcl | 293 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 67 |
| Omeprazole | Omeprazole | 287 | 73 |
| Montelukast Sodium | Montelukast Sodium | 279 | 64 |
| Alprazolam | Alprazolam | 275 | 47 |
| Lisinopril | Lisinopril | 270 | 67 |
| Glimepiride | Glimepiride | 259 | 60 |
| Celecoxib | Celecoxib | 250 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 241 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 48 |
| Carvedilol | Carvedilol | 230 | 43 |
| Lorazepam | Lorazepam | 227 | 38 |
| Furosemide | Furosemide | 225 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 40 |
| Jardiance | Empagliflozin | 201 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 35 |
| Eliquis | Apixaban | 192 | 39 |
| Tramadol Hcl | Tramadol Hcl | 192 | 39 |
| Potassium Chloride | Potassium Chloride | 189 | 51 |
| Allopurinol | Allopurinol | 188 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 36 |
| Spironolactone | Spironolactone | 186 | 47 |
| Simvastatin | Simvastatin | 184 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 51 |
| Nifedipine Er | Nifedipine | 174 | 31 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 157 | 36 |
| Metformin Hcl | Metformin Hcl | 155 | 33 |
| Mounjaro | Tirzepatide | 155 | 26 |
| Trazodone Hcl | Trazodone Hcl | 155 | 33 |
| Donepezil Hcl | Donepezil Hcl | 152 | 25 |
| Ozempic | Semaglutide | 148 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 125 | 28 |
| Clonazepam | Clonazepam | 119 | 26 |
| Famotidine | Famotidine | 114 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 21 |
| Januvia | Sitagliptin Phosphate | 107 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 20 |
| Sertraline Hcl | Sertraline Hcl | 100 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 16 |
| Ezetimibe | Ezetimibe | 96 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 81 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 19 |
| Pregabalin | Pregabalin | 87 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 82 | 17 |
| Farxiga | Dapagliflozin Propanediol | 80 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 16 |
| Estradiol | Estradiol | 76 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 23 |
| Trulicity | Dulaglutide | 74 | 11 |
| Linzess | Linaclotide | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 67 | 16 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Prednisone | Prednisone | 65 | 38 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Ondansetron Odt | Ondansetron | 64 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Azithromycin | Azithromycin | 63 | 52 |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Synthroid | Levothyroxine Sodium | 59 | 14 |
| Zaleplon | Zaleplon | 59 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Lansoprazole | Lansoprazole | 54 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 30 |
| Rybelsus | Semaglutide | 47 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Eszopiclone | Eszopiclone | 44 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Temazepam | Temazepam | 40 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 40 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 40 | suppressed |
| Colchicine | Colchicine | 39 | 12 |
| Novolog Flexpen | Insulin Aspart | 39 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Risperidone | Risperidone | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | 16 |
| Primidone | Primidone | 32 | suppressed |
| Nystatin | Nystatin | 31 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Valsartan | Valsartan | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,293.96 · 68 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, Extended Holter, FARXIGA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error